Search This Blog

Wednesday, October 28, 2026

PolyPid controlled-release doxycycline candidate for moderate to severe diabetic foot

 

PolyPid unveils PD01B Kynatrix-based controlled-release doxycycline candidate for moderate to severe diabetic foot infections, targets new NDA in 2027

  • Company outlines development plan targeting new NDA, with pre-IND and first-in-human study in second half 2027
  • PolyPid also provides updated D-PLEX100 regulatory and launch timelines for its ongoing program
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)